NCT05051696 is a Phase 2 clinical trial of H101 in Genital Neoplasms, Female, sponsored by Liu Zi.

Who is sponsoring NCT05051696?

NCT05051696 is sponsored by Liu Zi.

What drugs are being tested in NCT05051696?

Interventions in NCT05051696: H101.

What condition does NCT05051696 study?

NCT05051696 studies Genital Neoplasms, Female.

Is NCT05051696 still recruiting?

NCT05051696 is currently active, enrolled. Last updated 4 June 2024.

Last reviewed 2024-06-04 · How we verify

NCT05051696

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Active, enrolled Phase 2 Last updated 4 June 2024

What this trial tests

Phase 2 trial testing H101 in Genital Neoplasms, Female in 120 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

26 September 2021

Primary endpoint
30 March 2024

30 March 2025

Quick facts

Lead sponsor	Liu Zi
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	26 September 2021
Primary completion	30 March 2024
Estimated completion	30 March 2025
Sites	1 location across China

Drugs / interventions tested

H101 — full drug profile →

Conditions studied

Genital Neoplasms, Female — all drugs for Genital Neoplasms, Female →

Sponsor

Liu Zi

Who can join

18 and older, female only, with Genital Neoplasms, Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies. And further research the mechanism of oncolytic viruses H101.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Biomaterial-Based In Situ Cancer Vaccines.
Bo Y, Wang H. · · 2024 · cited 55× · PMID 36649567 · DOI 10.1002/adma.202210452
Tumor microbiome metabolism: A game changer in cancer development and therapy.
Zhou X, Kandalai S, Hossain F, Zheng Q. · · 2022 · cited 33× · PMID 35936744 · DOI 10.3389/fonc.2022.933407
Advances in the clinical development of oncolytic viruses.
Li K, Zhao Y, Hu X, Jiao J, et al · · 2022 · cited 33× · PMID 35836877
A Renaissance for Oncolytic Adenoviruses?
Blanchette P, Teodoro JG. · · 2023 · cited 18× · PMID 36851572 · DOI 10.3390/v15020358
Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer.
Huang X, Li XY, Shan WL, Chen Y, et al · · 2023 · cited 14× · PMID 37033645 · DOI 10.3389/fphar.2023.1131342
Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: A Retrospective Study.
Zhang J, Zhang Q, Liu Z, Wang J, et al · · 2022 · cited 14× · PMID 35574359 · DOI 10.3389/fonc.2022.877155
Therapeutic Implementation of Oncolytic Viruses for Cancer Immunotherapy: Review of Challenges and Current Clinical Trials.
Wang X, Maeng HM, Lee J, Xie C. · · 2022 · cited 5× · PMID 36381110 · DOI 10.36266/jbsr/164
Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy.
Zhang Q, Zhang J, Liu Z, Wang J, et al · · 2023 · cited 4× · PMID 38046281 · DOI 10.2147/dddt.s429180

Verify or expand the search:

Other trials of H101

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07398664 — H101 Plus TACE for r/m HNSCC · Phase 2 · not yet recruiting
NCT07381309 — Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM · Phase 2 · not yet recruiting
NCT06919848 — Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tr · Phase 2 · not yet recruiting
NCT05823987 — Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS · Phase 2 · unknown

Other recruiting trials for Genital Neoplasms, Female

Currently open trials in the same condition.

NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
NCT04807166 — Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer · Phase 2 · active not recruiting
NCT06741046 — RT for Cervical Adenocarcinoma/adenosquamous Carcinoma · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05051696 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Liu Zi
Last refreshed: 4 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05051696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing